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Background: Human papillomavirus type 16 (HPV16)-E6 antibodies are detectable in peripheral blood before diagnosis in the
majority of HPV16-driven oropharyngeal squamous cell carcinoma (OPSCC), but the timing of seroconversion is unknown.
Patients and methods: We formed the HPV Cancer Cohort Consortium which comprises nine population cohorts from
Europe, North America and Australia. In total, 743 incident OPSCC cases and 5814 controls provided at least one pre-diagnostic
blood sample, including 111 cases with multiple samples. Median time between first blood collection and OPSCC diagnosis was
11.4 years (IQR¼ 6–11 years, range¼ 0–40 years). Antibodies against HPV16-E6 were measured by multiplex serology (GST
fusion protein based Luminex assay).
Results: HPV16-E6 seropositivity was present in 0.4% of controls (22/5814; 95% CI 0.2% to 0.6%) and 26.2% (195/743; 95% CI
23.1% to 29.6%) of OPSCC cases. HPV16-E6 seropositivity increased the odds of OPSCC 98.2-fold (95% CI 62.1–155.4) in whites
and 17.2-fold (95% CI 1.7–170.5) in blacks. Seropositivity in cases was more frequent in recent calendar periods, ranging from
21.9% pre-1996 to 68.4% in 2005 onwards, in those with blood collection near diagnosis (lead time<5 years). HPV16-E6
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seropositivity increased with lead time: 0.0%, 13.5%, 23.7%, and 38.9% with lead times of>30 years (N¼ 24), 20–30 years
(N¼ 148), 10–20 years (N¼ 228), and<10 years (N¼ 301 cases) (p-trend< 0.001). Of the 47 HPV16-E6 seropositive cases with
serially-collected blood samples, 17 cases seroconverted during follow-up, with timing ranging from 6 to 28 years before
diagnosis. For the remaining 30 cases, robust seropositivity was observed up to 25 years before diagnosis.
Conclusions: The immune response to HPV16-driven tumorigenesis is most often detectable several decades before OPSCC
diagnosis. HPV16-E6 seropositive individuals face increased risk of OPSCC over several decades.
Key words: HPVC3, OPCSCC, oropharyngeal squamous cell carcinoma
Introduction
The chief causes of oropharyngeal squamous cell carcinoma
(OPSCC) are tobacco and alcohol use, as well as infection with
human papillomavirus type 16 (HPV16) [1]. In the United States
(US) and some other high-income western countries, the attrib-
utable fraction of OPSCC due to HPV now exceeds 70% [1].
Further, the incidence and burden of HPV-related OPSCC is
increasing, particularly for men [2–5], warranting potential
methods for early detection to be considered.
We initially reported that HPV16-E6 antibodies are detectable
in the circulation before diagnosis in a considerable proportion
of OPSCC cases in a European population, whilst being nearly
absent in controls [6]. We subsequently replicated those results
in a US cohort, and demonstrated that HPV16-E6 antibody levels
are stable up to a decade before diagnosis [7]; however, due to the
rarity of OPSCC, there were insufficient serial samples to describe
the timing of HPV16-E6 seroconversion among HPV16-driven
OPSCC cases.
To overcome this constraint, we formed the HPV Cancer
Cohort Consortium (HPVC3) to investigate HPV antibodies
and risk of all HPV-driven cancers [8], including oropharyn-
geal, anal, cervical, vaginal, vulvar, and penile cancers. Nine
prospective cohort studies participated, together providing a
study base exceeding 1.3 million participants from Europe,
North America, and Australia within which blood was collected
up to 40 years before cancer diagnosis. HPV serologic testing
was conducted for incident cancer cases and matched controls
simultaneously for antibodies against multiple HPV genotypes
and antigens. In this first HPVC3 manuscript where we focus
on the HPV16-E6 antibodies before diagnosis of OPSCC and
considers different lead times and periods of calendar time,
which is important given the temporal increases in the HPV16-
attributable fraction of OPSCC [9].
Methods
Prospective cohorts participating in the US National Cancer Institute
(NCI) cohort consortium were invited to participate in HPVC3. Nine
individual cohorts agreed to participate, including ATBC [10] (Years of
enrollment, 1985–1988), CLUE [11] (1974–1989), EPIC [12] (1991–
1999), HUNT [13] (1995–2008), JANUS [14] (1972–2004), MCCS [15]
(1990–1994), PLCO [16] (1993–2001), SCCS [17] (2002–2009), and
WHI [18, 19] (1994–1998), representing a total study base of over 1.3
million study participants. Details on design of the cohorts and their
follow-up procedures are provided in the supplementary Methods (avail-
able at Annals of Oncology online). All study participants provided
written informed consent for their samples to be used for research pur-
poses and the research project was approved by the Ethical Committees
and/or Institutional Review Board of each participating cohort.
Selection of cases and controls for HPVC3
Anogenital and head and neck cancer sites with an etiologic link to HPV
infection [8] were included in the HPVC3 study and classified based on
the International Classification of Diseases for Oncology. In total, 2808
anogenital and head and neck cancer cases with available plasma or
serum samples were identified within the participating cohorts. For each
HPVC3 eligible anogenital and head and neck cancer case, two controls
were randomly chosen from risk-sets consisting of all cohort members
alive and free of cancer (except non-melanoma skin cancer) at the time of
diagnosis of the index case. Matching criteria included cohort (and study
center where relevant), sex, date of blood collection (66 months, relaxed
to 612 months for sets without available controls, N¼ 68), and date of
birth (61 year, relaxed to 65 years, N¼ 52). A total of 5814 matched
controls with available plasma or serum samples and relevant data were
included in serologic analyses.
Of the 2808 eligible cancer cases in HPVC3, 825 were defined as oro-
pharyngeal cancer (OPC) cases of any histologic type (International
Classification of Diseases 10th Revision Clinical Modification; ICD-10-
CM: C01, C02.4, C02.8, C05.1, C05.2, C09.0, C09.1, C09.8, C09.9, C10.0,
C10.1, C10.2, C10.3, C10.4, C10.8, C10.9; supplementary Table S1, avail-
able at Annals of Oncology online). We focused this analysis on 743
(90.1%) cases classified as squamous cell carcinoma subtypes (OPSCC)
(ICD-03; 8051/3, 8052/3, 8070/2, 8070/3, 8071/3, 8072/3, 8073/3, 8074/3,
8076/3, 8082/3, 8083/3, 8094/3).
The current analysis was based on plasma or serum analysis from 743
OPSCC cases and all 5814 matched controls (n.b. use of all the controls,
and not just matched controls, is justified by the exceptionally
low HPV16 E6 seroprevalence in people without cancer, and its lack of
associations with covariates [20]; analyses subset to only matched con-
trols provided the same results albeit with wider confidence intervals).
We previously published data from EPIC [6] and PLCO [7] OPC cases
(n¼ 210); updated cancer linkages resulted in seven additional cases
from the PLCO study and 526 cases from the newly-added cohorts.
Serological analyses
Serum/plasma samples were sent on dry ice to the German Cancer
Research Center (DKFZ, Heidelberg, Germany) and testing was carried
out using multiplex serology by laboratory staff blinded to the case–
control status of the subjects. Antigens were affinity-purified, bacterially-
expressed fusion proteins with N-terminal Glutathione S-transferase
[21]. Samples were analyzed for antibodies to the early oncoprotein
HPV16-E6. Median fluorescence intensity (MFI) values were dichotom-
ized as antibody positive or negative using a pre-defined cut-off value of
1000 MFI as in our previous PLCO study [7]. Based on 72 subjects with
serum assayed in duplicate, the intra-class correlation coefficients (ICC)
for HPV16-E6 was 0.97 (95% CI 0.95–0.98).
Statistical analyses
Baseline characteristics of the cancer cases and controls were initially
tabulated and evaluated. Noted imbalances were the result of using all
available control data. Our pre-specified main analyses involved estimat-
ing HPV16-E6 seroprevalence for OPSCC cases overall, stratified by
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anatomical subsites within the oropharynx, and for controls. To provide
the most relevant representation of HPV16-E6 status for the OPSCC
cases, and considering the hypothesis that HPV16-E6 seroconversion can
occur both close to (i.e. within a few years) and long before (i.e. over
10 years) the clinical diagnosis of HPV-related OPSCC, we based our
main analysis on the HPV16-E6 antibody measure from the sample col-
lected closest to diagnosis for subjects with multiple pre-diagnostic blood
samples. Unadjusted (crude) odds ratios were calculated for OPSCC
overall and by anatomic subsites across all participating cohorts using
unconditional logistic regression. Of note, conditional or multivariable
logistic regression was not possible due to some cohorts lacking seroposi-
tive controls. HPV16-E6 seropositivity was stratified on sex and, given
suggestions in the literature of heterogeneity in the fraction of HPV-
related OPSCC [22], by race (US cohorts only; non-US cohorts included
only white study participants).
Further pre-specified analyses included evaluating differences in the
fraction of seropositive cases by lead time and by calendar time. To assess
lead time differences, we restricted cases to the most recent category of
calendar time (>2005) to control for known changes in HPV16-E6
DNA positivity over time [9]. Similarly, to assess calendar time differen-
ces in the fraction of seropositive cases, we restricted cases to those with
the shortest lead time (0–5 years). Trends in HPV16-E6 seroprevalence
were tested using simple logistic regression including the variable
(e.g. calendar time) as an ordinal covariate.
For OPSCC cases with multiple blood samples available before diagno-
sis, patterns of HPV16-E6 MFI levels were described graphically by
time before diagnosis and age, separately for three groups: cases who
were HPV16-E6 seronegative throughout follow-up, cases who were
HPV16-E6 seropositive throughout follow-up, and cases who serocon-
verted during follow-up. Seroconversion was defined as a change from
below to above the assay cut-off for seropositivity of 1000 MFI. We
described the longest and shortest lead times for individual samples and
additionally computed the median lead time as the average between the
time points just before and after the observed seroconversion. As this
assumes linearity in the immune response, we did sensitivity analyses
where the timing of seroconversion used the time point before as well as
the time point after seroconversion. Timing of HPV16-E6 seroconver-
sion was also evaluated using age as the time scale. All statistical analyses
were conducted using R version 3.5.0.
Results
Baseline characteristics
OPSCC cases and 5814 controls were identified from nine par-
ticipating cohorts (Table 1; supplementary Table S2, available
at Annals of Oncology online). The median age at study enroll-
ment and, therefore, first blood draw was 46 years [interquar-
tile range (IQR) 41–55]. The vast majority (94%) of study
participants were white, male (72.9% of cases compared with
62.2% of controls) and ever smokers (83.1% of cases and
65.0% of controls).
Among cases, median calendar year of diagnosis was 2004
(IQR 1999–2009) and median age at diagnosis was 62 years (IQR
57–68). Based on the sample collected closest to diagnosis, me-
dian lead time was 11.4 years (IQR 6–19; range 0–40 years);
43.1% of cases had samples collected <10 years before diagnosis,
32.4% between 10 and 20 years, 20.4% between 20 and 30 years,
and 3.4% had 30 years. Fifteen percent of cases had multiple
pre-diagnostic samples including subjects with 10 (n¼ 1), 8
(n¼ 1), 7 (n¼ 3), 6 (n¼ 18), 5 (n¼ 12), 4 (n¼ 14), 3 (n¼ 19),
and 2 (n¼ 43) samples, as well as 590 (85%) subjects who pro-
vided a single blood sample.
HPV16-E6 seropositivity in cases and controls
HPV16-E6 seropositivity was present in 22 of 5814 controls
(0.4%; 95% CI 0.2% to 0.6%); thus, the marker specificity for
cancer was 99.6% (95% CI 99.4% to 99.8%). HPV16-E6 sero-
positivity was present before diagnosis in 27.2% of white OPSCC
cases (191 of 701; 95% CI 24.0% to 30.7%) and 7.7% of black
OPSCC cases (3 of 39; 95% CI 2.0% to 21.7%; p for difference be-
tween white and black OPSCC cases <0.001; Table 2). Thus,
HPV16-E6 seropositivity was associated with a 98.2-fold increase
in the odds of OPSCC in whites (95% CI 62.1–155.4) and 17.2-
fold increase in odds in blacks (95% CI 1.7–170.5). HPV16-E6
seroprevalence was 28.0% (95% CI 24.3% to 32.0%) in males and
21.4% (95% CI 15.9% to 27.7%) in females (pdifference¼ 0.07).
The median age at diagnosis was 62 years (95% CI 56–68) for
HPV16-E6 seropositive cases and 68 years (95% CI 62–73) for
HPV16-E6 seronegative cases.
By anatomic subsite within the oropharynx, HPV16-E6 sero-
positivity was present before diagnosis in 36.9% of 328 tonsillar
cancers, 25.2% of 218 bases of tongue cancers, and 9.7% of 170
cases with cancer at other OPSCC anatomic subsites.
Trends in HPV16-E6 seropositivity in OPSCC cases
by lead time
Restricting to cases diagnosed most recently in calendar time
(>2005), overall HPV16-E6 seroprevalence was 27.9% (87 of 312
cases; 95% CI 23.1% to 33.3%). Amongst these 312 cases, those
with shorter lead time had incrementally higher HPV16-E6 sero-
prevalence: 68.4% (95% CI 43.5% to 83.4%) of 19 cases with lead
time <5 years, 45.0% (95% CI 29.6% to 61.3%) of 40 cases with
lead time 5–10 years, 34.3% (95% CI 25.6% to 44.1%) of 108
cases with lead time 10–20 years, 15.2% (95% CI 9.6% to 23.0%)
of 125 cases with lead time 20–30 years, and 0% (95% CI 0.0% to
20.0%) of 20 cases with lead time >30 years (p-trend< 0.001;
Figure 1 and supplementary Table S3, available at Annals of
Oncology online).
Trends in HPV16-E6 seropositivity in OPSCC cases
and controls by calendar time
Restricting to cases with shortest lead time (<5 years), the overall
HPV16-E6 seroprevalence was 43.0% (61 of 142 cases; 95% CI
34.8% to 51.2%); however, seroprevalence decreased from 68.4%
(95% CI 43.5% to 83.4%) of 19 cases diagnosed after 2005, to
45.1% (95% CI 34.7% to 55.8%) of 91 cases diagnosed between
1995 and 2005, and further to 21.9% (95% CI 9.9% to 40.4%) of
32 cases diagnosed before 1995 (p-trend< 0.001; Figure 1 and
supplementary Table S3, available at Annals of Oncology online).
HPV16-E6 seropositivity was present in 0.2% (95% CI 0.1% to
0.4%) of 3466 controls with blood drawn before 1995, 0.7%
(95% CI 0.4% to 1.3%) of 1808 controls with blood drawn be-
tween 1995 and 2005, and in 0.0% (95% CI 0.0% to 1.8%) of 23
controls with blood drawn after 2005.
Annals of Oncology Original article
Volume 30 | Issue 8 | 2019 doi:10.1093/annonc/mdz138 | 1337
D
ow
nloaded from
 https://academ
ic.oup.com
/annonc/article-abstract/30/8/1335/5510170 by O
ikeustiet. kirjasto user on 15 N
ovem
ber 2019
HPV16-E6 seroconversion
In assessment of 111 OPSCC cases with serial blood samples, 30
cases were robustly HPV16-E6 seropositive throughout the
follow-up up to 25 years before clinical diagnosis (Figure 2A) and
17 seroconverted during the follow-up, with only one case fluctu-
ating around the threshold for HPV16 E6 seropositivity
(Figure 2B). In these 17 cases, seroconversion took place up to
28 years before diagnosis but not <6 years before diagnosis (sup-
plementary Table S4, available at Annals of Oncology online).
Using the average of the time points before and after the observed
seroconversion, the median lead time was 11.5 years (IQR 6.5–
14.3). In the sensitivity analyses, the median lead time based on
the time point just before seroconversion was 17.9 years
(IQR 13.0–19.8) and based on the time point after observed sero-
conversion was 6 years (IQR 4.7–8.8). The remaining 64 individ-
uals were HPV16-E6 seronegative in all serial samples
(Figure 2C).
HPV16-E6 seropositivity was observed across the spectrum of
age at initial blood draw (Figure 3). In OPSCC cases who were
HPV16-E6 seropositive throughout follow-up (Figure 3A),
HPV16-E6 seropositivity was first observed in a participant
who was 38 years old. HPV16-E6 seroconversion was observed
Table 1. Characteristics of OPSCC cases and controls in the HPV Cancer Cohort Consortium (HPVC3)
OPSCC (N5 743) Controls (N5 5814)
Race, N
Whites 701 (94.3) 5509 (94.8)
Blacks 39 (5.2) 208 (3.6)
Others 3 (0.5) 97 (1.7)
Sex, N(%)
Male 542 (72.9) 3619 (62.2)
Female 201 (27.1) 2195 (37.8)
Smoking, N(%)a
Current 356 (54.4) 1739 (30.9)
Former 188 (28.7) 1919 (34.1)
Never 110 (16.8) 1969 (35.0)
Alcohol drinking, N(%)a
Current 304 (79.6) 3235 (79.6)
Former 68 (17.8) 691 (17.0)
Never 10 (2.6) 139 (3.4)
Age at blood draw, N(%)a
40 143 (20.2) 696 (13.1)
41–50 226 (31.9) 1130 (21.2)
51–60 183 (25.8) 1490 (28)
61–70 128 (18.1) 1625 (30.5)
70 29 (4.1) 388 (7.3)
Case-only characteristicsb
Calendar year at diagnosis
Median (IQR) 2004 (1999, 2009) –
Age at diagnosis
Median (IQR) 62 (57, 68) –
Years between blood draw and diagnosis
At the case levela
Median (IQR; range) 11.4 (6–19; 0–40)
N(%)
[0–10) 301 (42.94) –
[10–20) 228 (32.52) –
[20–30) 148 (21.11) –
30 24 (3.42) –
At the specimen levelc
Median (IQR; range) 11.4 (6–20; 0–42)
aLatest date of blood draw for serial samples was used for calculations.
bCalculations restricted to white ethnicity.
cCalculations including all samples for OPSCC cases with several blood draws (HUNT, JANUS, MCCS, and PLCO).
OPSCC, oropharyngeal squamous cell carcinoma.
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as early as age 38 years and as late and 79 years, median age at
seroconversion was 52 (IQR 44–64; Figure 3B and supplementary
Table S4, available at Annals of Oncology online).
Discussion
We evaluated circulating HPV16-E6 antibodies before diagnosis
of OPSCC in collaboration with nine prospective cohort studies
from the United States, Europe, and Australia. This enabled us
to describe temporal patterns of pre-diagnostic HPV16-E6
seropositivity and seroconversion for cases up to 40 years before
diagnosis. Based on data from 743 incident OPSCC cases, 111 of
whom had multiple pre-diagnostic blood samples available, we
demonstrated that HPV16-E6 seroconversion can occur several
decades before OPSCC diagnosis. HPV16-E6 seropositivity was
associated with a nearly 100-fold risk increase of OPSCC in
whites and 20-fold risk increase in blacks. Shorter time from
blood draw to diagnosis and more recent calendar years of diag-
nosis were also associated with higher HPV16-E6 seroprevalence.
We finally demonstrated, based on data from 5814 controls, that
HPV16-E6 seropositivity is exceptionally rare (0.4%) in individ-
uals who are OPSCC free.
This analysis allowed us to make several novel observations.
Most notably, based on OPSCC cases with multiple pre-
diagnostic samples, we observed wide variation in the timing of
HPV16-E6 seroconversion before diagnosis. Seroconversion was
estimated to occur just 6 years preceding OPSCC diagnosis, but
also up to 28 years prior, conservatively basing the timepoint for
seroconversion on the HPV16-E6 seropositive sample observed
proximal to diagnosis. Seroconversion also occurred broadly
across the age scale—the first observed seroconversion occurred
in individuals in their mid-30s but was also observed into the
mid-60s. Furthermore, HPV16-E6 seropositivity was substantial-
ly higher in whites compared with blacks. Despite the small sam-
ple size for black OPSCC cases (n¼ 39), this finding suggests that
OPSCC is substantially more often driven by HPV16 in United
States white patients than in black patients. Because HPV-related
OPSCC generally have better survival than HPV-negative
OPSCC, this observation may at least partly explain the survival
disparity in OPSCC by race [22].
Etiologic insights about the natural history of oropharyngeal
HPV infection and its progression to OPSCC can now be
Figure 1. Human papillomavirus type 16 (HPV16)-E6 seroprevalence
in oropharyngeal squamous cell carcinoma (OPSCC) white cases, by
lead and calendar time. This ﬁgure shows the impact of lead time in
5-year categories on HPV16-E6 seroprevalence in OPSCC cases, strati-
ﬁed by year of cancer diagnosis. HPV16-E6 seroprevalence increases
with decreasing lead time and in the most recent calendar year of
diagnosis.
Figure 2. Human papillomavirus type 16 (HPV16)-E6 antibody me-
dian ﬂuorescence intensity (MFI) value in serial samples from OPSCC
white cases over the time period leading up to the cancer diagnosis
(time 0), for cases who were HPV16-E6 seropositive throughout the
entire follow-up period (A), cases who seroconverted during follow-
up (B), and cases who were seronegative throughout follow-up
(C).The dashed line represents the assay cut-off for HPV16-E6 sero-
positivity, MFI> 1000. In (B), the case who seroconverted furthest
from cancer diagnosis is highlighted in green and the case with mul-
tiple measurements who stably seroconverted closest to diagnosis is
highlighted in blue. One case ﬂuctuated around the assay threshold
for positivity and is HPV16-E6 seropositive in one of their six available
serial samples.
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superimposed on what is known for HPV infections at other ana-
tomic sites where HPV causes cancer. For cervical HPV infec-
tions, it is well established that incident cervical HPV infection
most commonly occurs shortly after sexual debut and peaks in
their 20s [23]. In contrast, incidence of penile HPV infection
appears constant across the lifespan [24]. The patterns of
HPV16-E6 seroconversion that we observed in OPSCC cases,
with a median age of seroconversion at 52 years, suggest that ac-
quisition of oral HPV16 infection may happen later in life (20s
through 40s). This interpretation is bolstered by analyses of
prevalent oral HPV infection, where peak prevalence estimates
were observed at these older ages [25].
This work informs the potential for translating the HPV16-E6
biomarker into use for early detection of OPSCC. Given the
increasing incidence of OPSCC among men, along with the
increasing fraction of HPV-related OPSCC [4, 9], it is conceiv-
able that a screening program for OPSCC could eventually be
considered for selected high-risk groups. This is increasingly rele-
vant since prophylactic HPV vaccination, despite being highly ef-
fective against oral HPV16 infections [26, 27], will not affect rates
of OPSCC for decades, when vaccinated cohorts of adolescent
age move into the cancer-susceptible age range of 50–70 years.
Already, HPV16-E6 seropositivity is established as a highly sensi-
tive marker for HPV-driven OPSCC [28–30], and continued
studies document its exceptionally high specificity [20]—in this
analysis, 99.6%. Here, we additionally show that individual
OPSCC cases can be HPV16-E6 seropositive several decades be-
fore clinical presentation of the disease, which has major implica-
tions for potential use of the biomarker in clinical practice.
Specifically, if an HPV16-E6 screening program were in place,
one would expect screen-positive individuals to require years of
continued evaluation before clinically-actionable disease may
occur, leading to potential psychosocial harms including anxiety.
Importantly, an additional major challenge in an early detection
program is that we lack evidence-based actionable interventions
for screen-positive individuals, and translating the E6 biomarker
will likely require identification and description of an OPC pre-
cursor. Advances in diagnostics and treatment continue to be
researched in preparation for this future [31] and we assert that
HPV16-E6 should be an important tool in this research, as
HPV16-E6 seropositive men have a notable cumulative incidence
of future OPSCC [7].
The main limitation of this work is the inherent heterogeneity
between the participating cohorts. For example, most cases with
very long lead times came from the Norwegian JANUS cohort.
It is, therefore, difficult to determine whether the observed
HPV16-E6 seroprevalence in the longer lead times is attributed
to the lead time specifically, or to being in the JANUS cohort.
Unfortunately, there are few large cohort studies with both
serial blood draws and very long follow-up, which are both
required to understand HPV16-E6 seroconversion many years
before OPSCC diagnosis.
The etiological landscape for OPSCC is shifting [32], in
particular in western populations where the majority of OPSCC
are now caused by HPV. Further, birth cohorts who experienced
the increases in incidence at younger ages are now experiencing
increased incidence at older ages—these changes will continue
to influence the burden of this disease in younger and older
males, and possibly females [33]. While HPV vaccination holds
promise in preventing HPV-related cancer in general, a result-
ing diminution in OPSCC will not be observed for decades.
Thus, we must continue to carefully assess opportunities
for the early detection of OPSCC, including the use of HPV16-
E6 antibody detection. Together with other efforts, such as
improved diagnostic techniques and less-invasive treatments,
there may be a great opportunity to reduce the morbidity
and mortality from OPSCC that is forecasted to occur in the
coming years [31].
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